Trials / Completed
CompletedNCT03823911
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- University of Maryland, Baltimore · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is an interventional, non-randomized, controlled prospective study to treat HCV in mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV mono-infected controls. This pilot study will demonstrate whether functional cure of HCV reduces myocardial injury and risk of cardiovascular disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elbasvir / Grazoprevir Oral Tablet [Zepatier] | All approved direct-acting antivirals for hepatitis C will be used as the intervention. |
| PROCEDURE | Cardiac MRI | Cardiac MRI to assess for myocardial function and fibrosis |
Timeline
- Start date
- 2018-11-18
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2019-01-31
- Last updated
- 2023-05-22
- Results posted
- 2023-05-22
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03823911. Inclusion in this directory is not an endorsement.